Prenatal exposure to neuroinflammation (cytokines) may provide a biomarker for the risk of later development of Alzheimer's ...

Financial writer recommends Voyager Therapeutics, Inc. for high-risk investors due to promising preclinical Alzheimer's ...

Atherosclerosis risk is elevated in diabetic patients, but the underlying mechanism such as the involvement of macrophages remains unclear. Here, we investigated the underlying mechanism related to ...

We are delighted that QUELIMMUNE is now available to treat severely ill children at yet another prominent academic medical center,” said Tim Varacek, SeaStar Medical Senior Vice President, Commercial ...

Agreement grants Nippon Shinyaku an option to acquire exclusive U.S. rights to commercialize AB2 Bio’s Tadekinig alfa to treat Primary Monogenic ...

Tourmaline Bio, Inc. (NASDAQ:TRML – Get Free Report) has earned a consensus rating of “Buy” from the six analysts that are presently covering the stock, Ratings reports. Six equities research analysts ...

“You can get water kefir and dairy kefir,” Dr Rossi explains. “Dairy kefir is made with milk and contains lactose, unlike water kefir which is made with sugary water. Generally speaking, homemade ...

A 22-month survival benefit was seen for a subset of ALS patients whose disease did not progress when treated with NP001 in ...

CA inhibited the expressions of proinflammatory cytokines in DSS-induced colitis mice), and improved the integrity of the intestinal barrier (IDDF2024-ABS-0076 Figure 3. CA protected the colonic ...

This important study provides solid evidence to support the anti-tumor potential of citalopram, originally an anti-depression drug, in hepatocellular carcinoma (HCC). In addition to their previous ...

Despite the recent rise in herbal supplement use, research suggests certain supplements may pose risks for patients with autoimmune diseases.

AB2 Bio has entered into an option and licensing agreement with Nippon Shinyaku Co. Ltd., a leading Japanese pharmaceutical company with extensive experience in marketing rare disease therapeutics in ...